[{"id":"5549ff6d-d0c0-4524-812c-e784acd2dec2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04305444","created_at":"2021-01-18T20:52:47.509Z","updated_at":"2024-07-02T16:35:49.171Z","phase":"Phase 2","brief_title":"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT04305444","lead_sponsor":"Zhejiang DTRM Biopharma","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • DTRM-555 • DTRMWXHS-12"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-05-02"},{"id":"9b4cb9d9-27ad-4983-bcb4-e8b1c0081a9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03836768","created_at":"2021-01-18T18:56:33.448Z","updated_at":"2024-07-02T16:35:55.474Z","phase":"Phase 1","brief_title":"BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma","source_id_and_acronym":"NCT03836768","lead_sponsor":"Zhejiang DTRM Biopharma","biomarkers":" CCND1","pipe":"","alterations":" ","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DTRMWXHS-12"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/11/2019","start_date":" 01/11/2019","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 11/17/2021","study_completion_date":" 11/17/2021","last_update_posted":"2023-02-15"}]